Legal & General Group PLC Cellectis S.A. Transaction History

Legal & General Group PLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$3.45 - $8.77 $1.16 Million - $2.96 Million	-337,201 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$8.01 - $12.84 $964,155 - $1.55 Million	120,369 Added 55.51%	337,201 $2.74 Million
Q3 2021 Nov 15, 2021	BUY	$11.94 - $16.09 $131,817 - $177,633	11,040 Added 5.36%	216,832 $2.73 Million
Q2 2021 Aug 12, 2021	BUY	$14.36 - $20.93 $545,837 - $795,570	38,011 Added 22.66%	205,792 $3.18 Million
Q1 2021 May 17, 2021	BUY	$18.19 - $33.25 $2.21 Million - $4.04 Million	121,560 Added 263.0%	167,781 $3.39 Million
Q4 2020 Feb 12, 2021	BUY	$15.87 - $31.64 $24,915 - $49,674	1,570 Added 3.52%	46,221 $1.25 Million
Q3 2020 Nov 13, 2020	BUY	$15.7 - $20.84 $227,775 - $302,346	14,508 Added 48.13%	44,651 $826,000
Q2 2020 Aug 14, 2020	BUY	$8.21 - $21.02 $247,474 - $633,605	30,143 New	30,143 $537,000

11.2M

2.8K

17.9K

Ticker CLLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,510,800
Market Cap $91.9M
Description
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatm...

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

Stay updated on Legal & General Group PLC with notifications on news.